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Andrea Savarino1* and Enrico Garaci2Abstract
Our inability to cure HIV/AIDS is related to the ability of the virus to establish reservoirs during treatment. In order
to develop new strategies, it is certainly essential that a suitable animal model be implemented. In the recent work
of Shytaj et al., it has been possible to inhibit viral replication to levels below the assay detection limit in the
macaque AIDS model. Moreover, different therapeutic regimens applied to the rhesus macaque AIDS model (herein
reviewed), including ours, are starting to show the potential to induce, following therapy suspension, conditions
reminiscent of a drug-free control of the infection.
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Antiretroviral therapy (ART; usually a combination of
three drugs) is unable to completely eliminate the virus
from the infected organism. When the detection limit of
the standard assays (usually 50 copies of viral RNA/mL)
is decreased, persistence of low-level viremia is observ-
able in the majority of the individuals under ART [1].
Moreover, the eradication of the virus is hampered by
the existence of long-lived viral reservoirs, (mainly cen-
tral and transitional memory CD4+ T-cells), which har-
bor silent copies of proviral DNA that cannot be
targeted by antiretroviral drugs or the immune system
[2]. Mainstream experimental approaches for the
elimination of the viral reservoir include stem cell trans-
plantation to renovate the immune system [3], or the
“shock-and-kill” strategies, i.e. 1) intensified ART (iART)
with at least four drugs targeting viral replication at mul-
tiple steps, 2) induction of viral escape from latency
through specific antilatency drugs such as the histone
deacetylase inhibitors, and 3) elimination of the infected
cells through either viral cytopathogenicity, the immune
system or specific drugs [3,4] (Figure 1). An alternative
approach is aimed at decreasing the lifespan of the cen-
tral and transitional memory T-cell pools [5] (Figure 1).* Correspondence: andrea.savarino@iss.it
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distribution, and reproduction in any mediumNon-human primate models are suitable experimental
platforms for pre-clinical testing of investigational anti-
reservoir drugs discovered in the laboratory [6]. Due to
their close phylogenetic relationship with humans, maca-
ques (Macaca sp.) infected with sooty mangabay-derived
viruses (SIVmac), such as SIVmac251, represent interest-
ing models for studying the pathophysiology of HIV/
AIDS in humans; however, the paucity of antiretrovirals
able to cross-inhibit SIVmac rendered particularly diffi-
cult maintaining an undetectable viremia mimicking the
conditions of HIV-infected individuals under ART.Main text
The findings that SIVmac is susceptible to the nucleosi-
dic/nucleotidic reverse transcriptase inhibitors emtricita-
bine and tenofovir [6] and to the integrase inhibitor
raltegravir [7] were fundamental for the establishment of
current macaque models for suppressive ART regimens
that may also include the protease-inhibitor darunavir
boosted with ritonavir (iART) [5]. These drug cocktails
were shown to control viremia at undetectable levels for
prolonged periods in macaques in the early chronic SIV-
mac251 infection [5]. In a recent study coordinated by
our Institution, Shytaj et al. show that a five–drug regimen
(tenofovir/emtricitabine/raltegravir/darunavir/r/maraviroc),
dubbed highly-intensified ART (H-iART), can control
viremia to undetectable levels in a wider array of maca-
ques including, for the first time, those in pre-AIDS stageCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Schematic representation of the most likely viral reservoir dynamics in vivo and the possible anti-reservoir drug strategies
mentioned in the text. Briefly, latently infected cells proliferate by either homeostasis or antigen-driven activation. Part of the activated cells
becomes productively infected, spreading the virus to uninfected cells, while another portion either dies or reverts to a latent state. These
phenomena contribute to the expansion of the viral reservoir during lentiviral infections. If cell-to-cell viral spread is blocked by highly-intensified
antiretroviral therapy (H-iART), activation-driven proliferation and homeostatic proliferation represent the main mechanisms for the expansion/
persistence of the viral reservoir during therapy. One important component of H-iART, i.e. the CCR5 blocker maraviroc, was shown in a recent
study (Ref. [8]) also to decrease activation-induced proliferation of the central and transitional memory T-cells (encompassing the viral reservoir).
Antilatency drugs such as the histone deacetylase inhibitors may favor the transition of the activated latently infected cells to the productive class
[vulnerable to viral cytopathogenicity, specific immune responses, or pro-oxidant drugs auch as buthionine sulfoximine (BSO)] at the expense of
reversion of the same cells to the latent state. Finally, the gold salt auranofin, by decreasing the lifespan of the central and transitional memory
T-cells, restricts their potential to expand by both homeostatic and activation-driven proliferation. Adapted and modified from Ref. [14].
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copies/mL) [8]. This model was also suitable for providing
further insight into viral persistence during therapy.
By lowering the viral detection limit in plasma to 3 RNA
copies/mL, and by analyzing viral RNA in anatomical
compartments such as the rectum and inguinal lymph
nodes, no ongoing viral replication was detected in the
majority of the treated macaques [8]. One unexpected
finding was a likely decrease in the viral reservoir, as
shown by the occurrence of a three-phase decay of viral
DNA, with the third phase likely corresponding to the
decay of latently infected cells. This observation was sup-
ported by a decrease in the viral set-point following ther-
apy suspension. Potential anti-reservoir effects of the
CCR5 blocker maraviroc (i.e., the crucial component of
H-iART) were also observed in independent studies of
Gutierrez et al. and Ananworanich et al. in humans [9,10].
The aforementioned study of Shytaj et al. provides the
grounds for these results, showing that maraviroc
decreases activation-driven proliferation of the central and
transitional memory T-cells in-vitro (Figure 1) [8]. These
effects prompted evaluation of H-iART in combination
with more specific anti-reservoir strategies. In a pilotstudy, animals were treated with H-iART and the gold-
drug auranofin, which selectively kills the central and tran-
sitional memory-cells (encompassing the viral reservoir
[5]). Following treatment suspension, these animals dis-
played very low viral set-points (≤ 103 viral RNA copies/
mL) upon treatment interruption, though remaining per-
sistently viremic [8]. More surprising results, i.e. a drug-
free control of viremia, were obtained by re-treating with
a short H-iART cycle ( 1.5 months) at rebound (which
mimics a novel acute infection-like condition, i.e. a new
therapeutic window) [5,8] or by adding, to the HiART/
auranofin combination, buthionine sulfoximine [11] (BSO,
a drug previously shown to contribute to viral escape from
latency and selectively kill productively infected cells [4];
see Figure 1). Although safety issues will require further
evaluation, the treatments were well tolerated by the
macaques, thus suggesting that restriction/death of the
memory T-cells is relatively safe.
Van Rompay et al. [12] recently showed similar findings,
following an entirely different approach, i.e. treatment of
rhesus macaques both in the acute and early chronic
phase of SIVmac/RT-SHIV infection with a suboptimal
and discontinued antiretroviral regimen consisting of
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“functional cure”, defined as “a condition in which virus is
not eliminated but is controlled sufficiently by antiviral
immune responses so that drug treatment can be with-
drawn for prolonged periods of time” [12]. Both the
results of our group and those of Van Rompay et al.,
though obtained with substantially different approaches
that are not yet directly applicable to humans, open a win-
dow into a possible future scenario of a functional cure of
AIDS. In both cases, upon treatment suspension, the virus
attempts to escape the immune control but is consistently
brought back to very low or undetectable levels and can-
not reach a stably viremic set-point [8,11,12]. It will be
interesting in the future to investigate on possible com-
mon mechanisms sparked by the different therapeutic
approaches.
Conclusions
The aforementioned studies show that a condition close
to a functional cure, which had so far obtained only by
treating during acute infection (as an example, see Ref
[13]), is achievable pharmacologically in the chronic
phase of SIV infection in rhesus macaques. Of note,
these results have been obtained by following
approaches that have so far been underestimated by the
mainstream research for a cure of AIDS [3] and will
therefore merit appropriate consideration for further
mechanistic analysis, including mathematical modeling
[14], subsequent formulation of candidate treatment
protocols, and testing in larger numbers of macaques.
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